Biomarkers and therapies associated with Hutchinson-Gilford Progeria Syndrome
- 17 June 2026
- journal article
- review article
- Published by Elsevier in Ageing Research Reviews
- Vol. 120, 103209
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Biomarkers of Cellular Senescence and Aging: Current State‐of‐the‐Art, Challenges and Future PerspectivesAdvanced Biology, 2024
- Progerin induces a phenotypic switch in vascular smooth muscle cells and triggers replication stress and an aging-associated secretory signatureGeroScience, 2022
- Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson–Gilford progeria syndromeGeroScience, 2020
- Progress and challenges towards CRISPR/Cas clinical translationAdvanced Drug Delivery Reviews, 2020
- Metabolomic profiling suggests systemic signatures of premature aging induced by Hutchinson–Gilford progeria syndromeMetabolomics, 2019
- Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria SyndromeJAMA, 2018
- Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria SyndromeJAMA Cardiology, 2018
- Mechanisms of genome instability in Hutchinson-Gilford progeriaFrontiers in Biology, 2016
- Hutchinson–Gilford progeria syndrome as a model for vascular agingBiogerontology, 2015
- Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interferenceHuman Genetics, 2005